Marco Becilli
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
HLA-Haploidentical Anti-CD7 Chimeric Antigen Receptor (CAR) T Cells for Transplant-Naïve Patients With Refractory T-Cell Acute Lymphoblastic Leukemia.
Journal: American journal of hematology
Published: July 08, 2026
Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression.
Journal: Translational oncology
Published: May 18, 2026
Overcoming disease refractoriness through CD7-targeting CAR T cells in acute myeloid leukemia.
Journal: Molecular therapy. Oncology
Published: May 08, 2026
CD19 antigen: from tumor target to safety switch in CAR-T cell therapy.
Journal: Haematologica
Published: April 07, 2026
Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.
Journal: Haematologica
Published: February 25, 2026
Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013.
Journal: Journal of hematology & oncology
Published: February 08, 2026
Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: September 09, 2025
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.
Journal: Nature medicine
Published: August 19, 2025
Sensitivity of Pediatric Myelodysplastic Syndromes With Excess of Blasts With UBTF -TD to Venetoclax/Azacitidine.
Journal: American journal of hematology
Published: July 13, 2025
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: March 01, 2025
Last Updated: 09/26/2026